Literature DB >> 1797525

Potent substituted-3 beta-phenyltropane analogs of cocaine have cocaine-like discriminative stimulus effects.

R L Balster1, F I Carroll, J H Graham, R S Mansbach, M A Rahman, A Philip, A H Lewin, V M Showalter.   

Abstract

Two novel phenyltropane analogs of cocaine, 3 beta-(4-chlorophenyl) tropane-2 beta-carboxylic acid methyl ester (RTI-COC-31) and 3 beta-(4-methylphenyl) tropane-2 beta-carboxylic acid methyl ester (RTI-COC-32), were evaluated for cocaine-like discriminative stimulus effects in rats. Two groups of rats were trained to discriminate 10 mg/kg cocaine from saline using a standard 2-lever discrimination procedure with correct-lever responding reinforced under a fixed-ratio 20 schedule of food reinforcement. One group of rats was used to evaluate RTI-COC-31 and the unsubstituted-3 beta-phenyltropane reference compound WIN 35,065-2 in substitution tests. Another group of rats was used to evaluate RTI-COC-32. For purposes of comparison, a cocaine dose-effect curve was also determined in each group. Both RTI-COC-31 and RTI-COC-32, as well as WIN 35,065-2, substituted completely for cocaine. RTI-COC-31 was 26.8-fold and RTI-COC-32 was 6-fold more potent than cocaine for producing cocaine-lever responding. The potent cocaine-like effects of the RTI analogs in vivo correspond with their high affinities for a cocaine recognition site on the dopamine transporter, providing further evidence that this site may mediate behavioral effects of cocaine relevant to its abuse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1797525     DOI: 10.1016/0376-8716(91)90043-x

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  7 in total

1.  Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil.

Authors:  L H Gold; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

Review 2.  Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.

Authors:  R B Innis
Journal:  Eur J Nucl Med       Date:  1994-01

Review 3.  Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.

Authors:  F Ivy Carroll; James L Howard; Leonard L Howell; Barbara S Fox; Michael J Kuhar
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

4.  Preclinical evaluation of the abuse potential of the analgesic bicifadine.

Authors:  Katherine L Nicholson; Robert L Balster; Krystyna Golembiowska; Magdalena Kowalska; Joseph P Tizzano; Phil Skolnick; Anthony S Basile
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

5.  Cocaine-like discriminative stimulus effects of procaine, dimethocaine and lidocaine in rats.

Authors:  J H Graham; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.

Authors:  Emily M Jutkiewicz; Michelle G Baladi; Ziva D Cooper; Diwahar Narasimhan; Roger K Sunahara; James H Woods
Journal:  Ann Emerg Med       Date:  2008-11-14       Impact factor: 5.721

Review 7.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.